In Brief: ArthroCare/Boston Scientific
This article was originally published in The Gray Sheet
Enter agreement under which Boston Scientific acquires exclusive licensing rights to develop and market ArthroCare's Coblation technology for use in myocardial revascularization. Boston Scientific will pay licensing fees to Sunnyvale, California-based ArthroCare upon achievement of designated clinical and regulatory milestones, and royalties on sales of resulting products. Specific terms of the agreement were not disclosed. ArthroCare began marketing the technology in December 1995 for use in arthroscopic surgery following FDA clearance ("The Gray Sheet" Jan. 26, 1996, p. 22)...
You may also be interested in...
Stryker Corp. agreed to license ArthroCare's Coblation radiofrequency arthroscopy technology just days after its mid-June launch of the competing Serfas arthroscopy product in order to head-off a patent infringement suit, ArthroCare says.
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.